Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 22 |
| Active Pipeline (Recruiting Now) | 5 (5) |
| Completed vs Stopped Early | 10 / 7 (31.8%) |
| Median Closed Actual Enrollment | 187 participants |
| Physical Hospital Site Disclosure | 99.6% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | 6 |
| Washington University and Siteman Cancer Center | Saint Louis, MO | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07095465 | Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | Phase III | RECRUITING |
| NCT07029581 | Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis | Phase II | RECRUITING |
| NCT07284667 | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase II | RECRUITING |
| NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | Phase II/III | RECRUITING |
| NCT04181723 | Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the ACADIA Pharmaceuticals Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.